Text stringlengths 636 34.6k |
|---|
Drug A is Abaloparatide. Drug B is Methyldopa. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Methyldopa is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Methylene blue. The severity of the interaction is moderate. Methylene blue may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive d... |
Drug A is Abaloparatide. Drug B is Metolazone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Metolazone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Metoprolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Metoprolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Metyrosine. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Metyrosine. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopa... |
Drug A is Abaloparatide. Drug B is Minoxidil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Minoxidil is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Moclobemide. The severity of the interaction is moderate. Moclobemide may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs i... |
Drug A is Abaloparatide. Drug B is Moexipril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Moexipril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Morphine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Morphine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Moxonidine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Moxonidine. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Nabilone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nabilone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Nadolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nadolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension, ... |
Drug A is Abaloparatide. Drug B is Nebivolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nebivolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Nicardipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nicardipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Nicorandil. The severity of the interaction is minor. Nicorandil may increase the hypotensive activities of Abaloparatide. Nicorandil is an agent that induces the relaxation of vascular smooth muscle, and is associated with a risk for developing severe hypotension as an adverse event.... |
Drug A is Abaloparatide. Drug B is Nifedipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nifedipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Nilvadipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Nilvadipine. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Nimodipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nimodipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Nisoldipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nisoldipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Nitrendipine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nitrendipine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Nitric Oxide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Nitroglycerin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Nitroprusside. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Nitroprusside is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Nitrous acid. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Nitrous acid. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Obinutuzumab. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Obinutuzumab. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Olanzapine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Olanzapine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Olmesartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Olmesartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Opicapone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Opicapone. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Paclitaxel. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Papaverine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Papaverine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Penbutolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Penbutolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Pentobarbital. The severity of the interaction is moderate. Pentobarbital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to danger... |
Drug A is Abaloparatide. Drug B is Perindopril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Perindopril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Phenelzine. The severity of the interaction is moderate. Phenelzine may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in ... |
Drug A is Abaloparatide. Drug B is Phenobarbital. The severity of the interaction is moderate. Phenobarbital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to danger... |
Drug A is Abaloparatide. Drug B is Phenoxybenzamine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of se... |
Drug A is Abaloparatide. Drug B is Phentolamine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Phentolamine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Pindolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Pindolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Polythiazide. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Polythiazide. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postme... |
Drug A is Abaloparatide. Drug B is Pramipexole. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Pramipexole is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Prazosin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Prazosin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Primidone. The severity of the interaction is moderate. Primidone may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerous hypo... |
Drug A is Abaloparatide. Drug B is Procaine. The severity of the interaction is moderate. Procaine may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in pres... |
Drug A is Abaloparatide. Drug B is Procarbazine. The severity of the interaction is moderate. Procarbazine may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs... |
Drug A is Abaloparatide. Drug B is Propofol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Propofol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Propranolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Propranolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Quetiapine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Quetiapine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Quinapril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Quinapril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Ramipril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Ramipril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension... |
Drug A is Abaloparatide. Drug B is Rasagiline. The severity of the interaction is moderate. Rasagiline may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in ... |
Drug A is Abaloparatide. Drug B is Remifentanil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Remifentanil is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Rilmenidine. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Rilmenidine. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmeno... |
Drug A is Abaloparatide. Drug B is Riociguat. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Riociguat. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Risperidone. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Risperidone. Risperidone may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titrati... |
Drug A is Abaloparatide. Drug B is Ropinirole. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Ropinirole is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Ropivacaine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Ropivacaine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Rotigotine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Rotigotine. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Safinamide. The severity of the interaction is moderate. Safinamide may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in ... |
Drug A is Abaloparatide. Drug B is Secobarbital. The severity of the interaction is moderate. Secobarbital may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerou... |
Drug A is Abaloparatide. Drug B is Selegiline. The severity of the interaction is moderate. Selegiline may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive drugs in ... |
Drug A is Abaloparatide. Drug B is Selexipag. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Selexipag. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopaus... |
Drug A is Abaloparatide. Drug B is Sevoflurane. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Sevoflurane is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Sildenafil. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Sildenafil is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension, par... |
Drug A is Abaloparatide. Drug B is Sodium ferric gluconate complex. The severity of the interaction is moderate. The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Abaloparatide. Ferrlecit may cause clinically significant hypotension. 1 Hypotension associated with... |
Drug A is Abaloparatide. Drug B is Sotalol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Sotalol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension, ... |
Drug A is Abaloparatide. Drug B is Spironolactone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Spironolactone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe... |
Drug A is Abaloparatide. Drug B is Streptokinase. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Streptokinase is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe h... |
Drug A is Abaloparatide. Drug B is Sufentanil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Sufentanil is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Tadalafil. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Tadalafil. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopaus... |
Drug A is Abaloparatide. Drug B is Tamsulosin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Tamsulosin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Telmisartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Telmisartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Terazosin. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Terazosin is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Thalidomide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Thalidomide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Thiopental. The severity of the interaction is moderate. Thiopental may increase the hypotensive activities of Abaloparatide. The use of barbiturates may increase hypotension. 1,2 Therefore, the concomitant administration of barbiturates and hypotensive agents may lead to dangerous hy... |
Drug A is Abaloparatide. Drug B is Thioridazine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Thioridazine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Timolol. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Timolol is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotension, ... |
Drug A is Abaloparatide. Drug B is Tizanidine. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Tizanidine is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Tolcapone. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Tolcapone is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Torasemide. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Torasemide is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Trandolapril. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Trandolapril is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hyp... |
Drug A is Abaloparatide. Drug B is Tranylcypromine. The severity of the interaction is moderate. Tranylcypromine may increase the orthostatic hypotensive activities of Abaloparatide. Incidences of orthostatic hypotension have occurred with monoamine oxidase inhibitors (MAOIs) therapy 1. Co-administration of hypotensive... |
Drug A is Abaloparatide. Drug B is Treprostinil. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Treprostinil. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postme... |
Drug A is Abaloparatide. Drug B is Triamterene. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Triamterene is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypot... |
Drug A is Abaloparatide. Drug B is Udenafil. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Udenafil is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension, particu... |
Drug A is Abaloparatide. Drug B is Valsartan. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Valsartan is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Vardenafil. The severity of the interaction is minor. The risk or severity of hypotension can be increased when Vardenafil is combined with Abaloparatide. The subject drug is a phosphodiesterase 5 inhibitor which can lower blood pressure. 1 The affected drug can cause hypotension, par... |
Drug A is Abaloparatide. Drug B is Verapamil. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Verapamil is combined with Abaloparatide. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypotensi... |
Drug A is Abaloparatide. Drug B is Vericiguat. The severity of the interaction is minor. The risk or severity of adverse effects can be increased when Abaloparatide is combined with Vericiguat. Co-administration of agents that are both associated with a risk for developing hypotension, including cases of severe hypoten... |
Drug A is Abaloparatide. Drug B is Zofenopril. The severity of the interaction is minor. Abaloparatide may increase the hypotensive activities of Zofenopril. The use of two drugs that both lower blood pressure may result in a more pronounced hypotensive effect. Abaloparatide is indicated for the treatment of postmenopa... |
Drug A is Abatacept. Drug B is Abemaciclib. The severity of the interaction is major. The metabolism of Abemaciclib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels... |
Drug A is Abatacept. Drug B is Abrocitinib. The severity of the interaction is moderate. The metabolism of Abrocitinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Acalabrutinib. The severity of the interaction is major. The metabolism of Acalabrutinib can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine le... |
Drug A is Abatacept. Drug B is Acebutolol. The severity of the interaction is moderate. The metabolism of Acebutolol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine level... |
Drug A is Abatacept. Drug B is Acenocoumarol. The severity of the interaction is major. The metabolism of Acenocoumarol can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine le... |
Drug A is Abatacept. Drug B is Acetaminophen. The severity of the interaction is moderate. The metabolism of Acetaminophen can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine... |
Drug A is Abatacept. Drug B is Acetylsalicylic acid. The severity of the interaction is moderate. The metabolism of Acetylsalicylic acid can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that r... |
Drug A is Abatacept. Drug B is Acyclovir. The severity of the interaction is moderate. The metabolism of Acyclovir can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels ... |
Drug A is Abatacept. Drug B is Adalimumab. The severity of the interaction is moderate. The risk or severity of infection can be increased when Adalimumab is combined with Abatacept. Since adalimumab and abatacept are both immunosuppressants, co-administration of adalimumab and abatacept can increase the risk of infect... |
Drug A is Abatacept. Drug B is Agomelatine. The severity of the interaction is moderate. The metabolism of Agomelatine can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Drug A is Abatacept. Drug B is Albendazole. The severity of the interaction is moderate. The metabolism of Albendazole can be increased when combined with Abatacept. The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine lev... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.